

- pathophysiology of, 333e-3, 333e-3f
 potassium regulation, 333e-2-3, 1814
 secondary hyperparathyroidism, 1815, 2478-2479
 treatment of, 1816, 2478-2479, 2485
 tumoral calcinosis, 1815, 1815f
- cardiovascular disorders in
 epidemiology of, 1816, 1816f
 gangrenous calcification, 462e-19
 heart failure, 1817
 hypertension, 201f, 1615, 1617, 1817
 ischemic vascular disease, 1816-1817
 left ventricular hypertrophy, 1817
 pericardial disease, 1575, 1817-1818
 risk factors for, 1825
 treatment of, 1817
- classification of, 1811, 1812f
 clinical features of, 289t
 contrast agent use in, 1461
 deaths from, 6e-1t, 11t, 56t
 diagnosis of, 289t
 drug concentration and response and, 37
 endocrine-metabolic disturbances in, 1819, 2366
 epidemiology of, 1813
 etiology of, 1813, 1813t
 diabetes mellitus. *See* Diabetic nephropathy
 glomerulonephritis, 1813. *See also* Glomerulonephritis
 urinary tract obstruction, 1873
- in Fabry's disease, 432e-1
 fluid, electrolyte, and acid-base disorders in
 acid-base regulation, 333e-3
 edema, 252, 252t
 hyperkalemia, 64e-2, 310
 hypokalemia, 307, 1814
 hyponatremia, 299, 1814
 metabolic acidosis, 318, 320, 1814
 sodium regulation, 333e-3, 1814
 treatment of, 320, 1815
 water regulation, 1814
- gastrointestinal and nutritional abnormalities in, 1819
 genetic considerations in, 332e-7t, 1811-1812
 global considerations in, 1821, 1822, 1825
 glomerular filtration rate in, 290-291, 1813t
 hematologic abnormalities in
 abnormal hemostasis, 1818
 bleeding, 404
 etiology of, 1818, 1818t
 hypoproliferative anemia, 398, 630, 630t
 high-altitude travel and, 476e-5-6
 immunization in, 788f
 lipoprotein disorders in, 2441
 in multiple myeloma, 714
 neuromuscular disorders in, 1818-1819
 back pain, 118
 coma, 1773
 delirium, 169
 fatigue, 152
 gait disorders, 164
 myopathy, 462e-19
 neuropathy, 1819, 2683-2684
 pathophysiology of, 1811, 1813f
 counterbalance, 333e-2
 inflammation, 1814
 nephron hyperfunction, 333e-1, 333e-1f, 1812f
 tubular hypertrophy, 333e-1, 333e-1f
 uremic syndrome, 1811, 1813, 1814
 in pregnancy, 46, 1819
 renal response to, 333e-2-3, 333e-2f, 333e-2t, 1812f
 risk factors for, 1811-1812
 in Sjögren's syndrome, 64e-7
 skin manifestations of, 362, 363, 462e-19, 1819
 in SLE. *See* Lupus nephritis
 stage 5 (end-stage renal disease)
 cardiovascular disease and, 1825
 in HIV infection, 1259
 hypertension in, 1847-1848
 incidence of, 1822
- treatment of, 1822. *See also* Hemodialysis; Kidney transplantation; Peritoneal dialysis
 uremic syndrome in, 1811, 1813
- treatment of
 antihypertensive therapy, 1820-1821
 diabetic nephropathy. *See* Diabetic nephropathy
 erythropoietin, 631
 medication dose adjustment, 1821
 patient education, 1821
 preparation for renal replacement therapy, 1821. *See also* Hemodialysis; Kidney transplantation; Peritoneal dialysis
 specialized nutritional support, 98e-4
 timing of renal replacement therapy, 1821
 tuberculous, 1110, 1110f, 1119-1120
- Chronic lymphoid leukemia. *See* B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma
- Chronic mountain sickness, 248, 476e-5
- Chronic myeloid leukemia (CML), **687**
 accelerated blastic phase of, 690
 atypical (*BCR-ABL1* negative), 135e-5-6, 135e-5t
 blastic phase of, 690
 cancer stem cells in, 102e-11
 chromosome abnormalities in, 687-689, 688f
 amplifications, 101e-2t
 translocations, 83e-7, 101e-3, 101e-3t, 101e-4f, 672, 687-688
 clinical features of, 689, 689t
 diagnosis of, 689-690
 epidemiology of, 687
 etiology of, 687
 global considerations in, 694-695, 694f
 incidence of, 687
 pathophysiology of, 687-689
 peripheral blood smear in, 81e-10f
 prognosis of, 690-691, 690f
 skin manifestations of, 369
 splenomegaly in, 411
 treatment of, **691**, 693t
 in accelerated or blastic phases, 693-694
 chemotherapy, 694
 goals for, 692
 HSCT, 139e-5t, 139e-6, 692-693, 693t
 interferon, 691, 694
 leukapheresis, 694
 monitoring, 693
 in pregnancy, 694
 splenectomy, 412, 694
 tyrosine kinase inhibitors, 101e-3, 102e-3-4, 102e-5t, 103e-16, 691-692, 691t, 693t
- Chronic myelomonocytic leukemia (CMML), 102e-3, 135e-5t, 135e-6, 669
- Chronic neutrophilic leukemia, 135e-5-6, 135e-6t, 672
- Chronic nonspherocytic hemolytic anemia, 656
- Chronic obstructive pulmonary disease (COPD)
 vs. asthma, 1676
 cor pulmonale in, 1506, 1704. *See also* Cor pulmonale
 CT in, 1705, 1705f
 deaths from, 1700
 definition of, 1700
 dyspnea in, 47e-1t, 47e-2, 47e-2t, 47e-3, 1704
 ECG in, 269e-12f, 278e-5f
 exacerbations of, 1706-1707
H. influenzae infections in, 1011
M. catarrhalis infections in, 1013, 1014f
 mechanical ventilation for, 1707
 noninvasive ventilation for, 1707, 1740
 genetic considerations in, 1703
 history in, 1704
 incidence of, 1700
 laboratory findings in, 1704-1705, 1704t
 natural history of, 1703-1704, 1704f
 pathogenesis of, 1700-1701, 1700f
 pathology of, 1701
- pathophysiology of, 41-42
 physical findings in, 1704
 risk factors for, 1702-1703, 1702f
 severity of, GOLD criteria for, 1704t
 in travelers, 799
 treatment of
 lung transplantation, 320e-1t, 1706
 lung volume reduction surgery, 1706
 pharmacotherapy, 1705-1706
 pulmonary rehabilitation, 1706
 smoking cessation, 1704
- Chronic pancreatitis, **2098**
 approach to the patient, 2088f
 clinical features of, 269, 284, 366, 2099-2100
 cobalamin absorption in, 350e-1, 350e-1t
 complications of, 2100, 2100t
 diagnosis of
 approach to, 2086, 2088f
 endoscopic, 1900
 imaging, 2087t, 2088-2089, 2089t
 imaging in, 2099-2100, 2100f
 Schilling test, 1941t
 epidemiology of, 2086
 etiology of, 2098-2099, 2098t
 genetic considerations in, 2098-2099
 pathophysiology of, 2098
 treatment of, 2100-2101, 2101t
- Chronic progressive external ophthalmoplegia. *See* Progressive external ophthalmoplegia
- Chronic Respiratory Disease Questionnaire, 47e-2
- Chronic traumatic encephalopathy, 173, 457e-4, 471e-2, 2608
- Chronic venous disease, **1650**
 anatomic considerations, 1650
 classification of, 1651, 1652t
 clinical features of, 1651, 1651f
 diagnosis of, 1651-1652
 differential diagnosis of, 1651
 epidemiology of, 1650
 pathophysiology of, 1650-1651
 treatment of, 1651-1652
- Chronic wasting disease (CWD), 453e-1t, 453e-2
- Chronotropic incompetence, 1468
- Chryseobacterium indologenes* infections, 183e-2t, 183e-3
- Chryseobacterium meningosepticum* infections. *See* *Elizabethkingia meningoseptica* infections
- Chrysiasis, 361
- Churg-Strauss syndrome. *See* Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- Chvostek's sign, 315
- Chylomicron(s), 1241t, 1936, 2437, 2437f
- Chylomicronemia syndromes, familial, 2439-2440, 2440t
- Chylothorax, 1718
- Ciclopirox, 347, 1358
- Cidofovir
 action of, 215e-7, 897
 for adenovirus, 1208
 adverse effects of, 897, 1804
 for CMV infection, 215e-2t, 215e-7, 922, 1194, 2657
 for CMV infection prophylaxis in HIV infection, 1252t
 for HHV-6 infections, 922
 for HSV infections, 1182-1183
 for molluscum contagiosum, 220e-1
 pharmacology of, 215e-7
 for smallpox, 261e-6
 for viral encephalitis, 897
- CIDP (chronic inflammatory demyelinating polyneuropathy), 2696t, **2698**
- Cigarette smoking. *See* Smoking
- Cigar smoking, 476
- Ciguatera poisoning, 267, 2742, 2742t
- CIITA, 373e-3
- Cilansetron, 1970
- Cilium, 1851f
- Cilostazol, 1645